Total oxidant and antioxidant status and paraoxonase 1 levels of children with noncystic fibrosis bronchiectasis
Total oxidant and antioxidant status and paraoxonase 1 levels of children with noncystic fibrosis bronchiectasis
Background/aim: To evaluate total oxidant status (TOS), total antioxidant capacity (TAC), and paraoxonase 1 (PON1) levels in childrenwith noncystic fibrosis (CF) bronchiectasis (BE), and to compare these levels with those of healthy controls. The study parameters werealso evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions.Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls. Serum TOS, TAC, and PON1levels were determined. Lung function tests were performed by spirometry.Results: Serum TOS was higher in the patients [median 9.54 (IQR 25–75 = 7.05–13.30) μmol H2O2 Eq/L] than in the healthy subjects[6.64 (5.45–9.53) μmol H2O2 Eq/L] (P < 0.001). TAC was higher in patients with non-CF BE [1.07 (1.0–1.07) mmol Trolox Eq/L] thanin the healthy controls [0.87 (0.77–0.98) mmol Trolox Eq/L] (P < 0.001). In addition, serum PON1 levels were significantly higher inthe patients [106.5 (42.5–154.2) U/L] than in the controls [47.7 (27.5–82.1) U/L] (P < 0.001). The patients with low FEV1 had decreasedTAC when compared to those who had normal FEV1 in non-CF BE.Conclusion: The present study demonstrated that compared with the control group the children with non-CF BE had elevated oxidativestatus, antioxidant defenses parameters, and PON1 values.
___
- 1. Pasteur MC, Bilton D, Hill AT; British Thoracic Society
Bronchiectasis non-CF Guideline Group. British Thoracic
Society Guideline for non-CF bronchiectasis. Thorax 2010; 65:
1-58.
- 2. Bergin DA, Hurley K, Mehta A, Cox S, Ryan D, O’Neill SJ,
Reeves EP, McElvaney NG. Airway inflammatory markers
in individuals with cystic fibrosis and non-cystic fibrosis
bronchiectasis. J Inflamm Res 2013; 6: 1-11.
- 3. MacNee W. Oxidative stress and lung inflammation in airways
disease. Eur J Pharmacol 2001; 429: 195-207.
- 4. Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara
K, Avgousti M, Amargianitakis V, Gousiou A, Menikou S,
Siafakas NM. Oxidative DNA damage and somatic mutations:
a link to the molecular pathogenesis of chronic inflammatory
airway diseases. Chest 2012; 141: 1243-1250.
- 5. Heunks LMA, Dekhuijzen PN. Respiratory muscle function
and free radicals: from cell to COPD. Thorax 2000; 55: 704-716.
- 6. Litvinov D, Mahini H, Garelnabi M. Antioxidant and
anti-inflammatory role of paraoxonase 1: antioxidant and
anti-inflammatory role of paraoxonase 1: implication in
arteriosclerosis diseases. N Am J Med Sci 2012; 4: 523-532.
- 7. Mackness M, Mackness B. Targeting paraoxonase-1 in
atherosclerosis. Expert Opin Ther Targets 2013; 17: 829-837.
- 8. Nadeem A, Chhabra SK, Masood A, Raj HG. Increased
oxidative stress and altered levels of antioxidants in asthma. J
Allergy Clin Immunol 2003; 111: 72-78.
- 9. Soler N, García-Heredia A, Marsillach J, Mackness B, Mackness
M, Joven J, Romero P, Camps J. Paraoxonase-1 is associated
with corneal endothelial cell alterations in patients with
chronic obstructive pulmonary disease. Invest Ophthalmol Vis
Sci 2013; 54: 5852-5858.
- 10. Back EI, Frindt C, Nohr D, Frank J, Ziebach R, Stern M, Ranke
M, Biesalski HK. Antioxidant deficiency in cystic fibrosis:
when is the right time to take action? Am J Clin Nutr 2004; 80:
374-384.
- 11. Lezo A, Biasi F, Massarenti P, Calabrese R, Poli G, Santini B,
Bignamini E. Oxidative stress in stable cystic fibrosis patients:
do we need higher antioxidant plasma levels? J Cyst Fibros
2013; 12: 35-41.
- 12. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in
idiopathic bronchiectasis: cellular and molecular mechanisms.
Eur Respir J 2008; 31: 396-406.
- 13. Tarpey MM, Wink DA, Grisham MB. Methods for detection
of reactive metabolites of oxygen and nitrogen: in vitro and in
vivo considerations. Am J Physiol, Reg Integr Comp Physiol
2004; 286: 431-444.
- 14. Erel O. A new automated colorimetric method for measuring
total oxidant status. Clin Biochem 2005; 38: 1103-1111.
- 15. Erel O. A novel automated method to measure total antioxidant
response against potent free radical reactions. Clin Biochem
2004; 37: 112-119.
- 16. Bonovita J, Naidich DP. Imaging of bronchiectasis. Clin Chest
Med 2012; 32: 233-248.
- 17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R,
Coates A. Standardization of spirometry. Eur Respir J 2005; 26:
319-338.
- 18. Eckerson HW, Wyte CM, La Du BN. The human serum
paraoxonase/arylesterase polymorphism. Am J Hum Genet
1983; 35: 1126-1138.
- 19. Henricks PA, Nijkamp FP. Reactive oxygen species as mediators
in asthma. Pulm Pharmacol Ther 2001; 14: 409-420.
- 20. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A.
Biomarkers of oxidative damage in human disease. Clin Chem
2006; 52: 601-623.
- 21. Riedl MA, Nel AE. Importance of oxidative stress in the
pathogenesis and treatment of asthma. Curr Opin Allergy Clin
Immunol 2008; 8: 49-56.
- 22. Selek S, Aslan M, Horoz M, Celik H, Cosar N, Gunak F,
Kocyigit A. Peripheral DNA damage in active pulmonary
tuberculosis. Environ Toxicol 2012; 27: 380-384.
- 23. Cristóvão C, Cristóvão L, Nogueira F, Bicho M. Evaluation
of the oxidant and antioxidant balance in the pathogenesis
of chronic obstructive pulmonary disease. Rev Port Pneumol
2013; 19: 70-75.
- 24. Rai RR, Phadke MS. Plasma oxidant-antioxidant status in
different respiratory disorders. Indian J Clin Biochem 2006;
21: 161-164.
- 25. Olveira G, Olveira C, Dorado A, García-Fuentes E, Rubio E,
Tinahones F, Soriguer F, Murri M. Cellular and plasma oxidative
stress biomarkers are raised in adults with bronchiectasis. Clin
Nutr 2013; 32: 112-117.
- 26. Cakmak A, Zeyrek D, Atas A, Celik H, Aksoy N, Erel O.
Serum prolidase activity and oxidative status in patients with
bronchial asthma. J Clin Lab Anal 2009; 23: 132-138.
- 27. Koc S, Aksoy N, Bilinc H, Duygu F, Uysal IÖ, Ekinci A.
Paraoxonase and arylesterase activity and total oxidative/antioxidative
status in patients with chronic adenotonsillitis. Int J
Pediatr Otorhinolaryngol 2011; 75: 1364-1367.
- 28. Rumora L, Rajković MG, Kopčinović LM, Pancirov D, Cepelak
I, Grubišić TZ. Paraoxonase 1 activity in patients with chronic
obstructive pulmonary disease. COPD 2014; 11: 539-545.
- 29. Acay A, Erdenen F, Altunoglu E, Erman H, Muderrisoglu C,
Korkmaz GG, Gelisgen R, Tabak O, Uzun H. Evaluation of
serum paraoxonase and arylesterase activities in subjects with
asthma and chronic obstructive lung disease. Clin Lab 2013;
59: 1331-1337.